



Press Release

21 April 2011

Gamma Vaccines is a vaccine development company aimed at solving one of the holy grails of infectious diseases – the creation of a universal flu vaccine. Today, we are pleased to announce that PT Soho Industri Pharmasi will make a follow-on investment of \$560,000 to support the Company's R&D, business development and intellectual property portfolio. This investment follows their earlier seed investment of \$600,000 in December 2009.

Professor Tim Hirst, Executive Chairman of Gamma Vaccines commented "We are delighted by PT Soho Industri Pharmasi's continuing commitment as a cornerstone investor in Gamma Vaccines. The relationship with Soho has created considerable leverage and opportunity for us to pursue a Global Health Initiative, particularly within Indonesia, as well as providing much needed resources to pursue our core development program on GammaFlu®.

Dr Marcus Pitt, CEO of The Soho Group said "This is an important investment for PT Soho Industri Pharmasi. We have forged an excellent partnership with Gamma Vaccines and we see the investment in innovative new products as a core part of The Soho Group's long term growth strategy.

For Further Information, please contact Tim Hirst on +61 420 942 824

About Gamma Vaccines

Gamma Vaccines is headquartered in Canberra, Australia. It was established in 2009 to develop GammaFlu®, a universal flu vaccine that is expected to do away with the need to produce new influenza vaccines each year. GammaFlu® is also being designed to be effective against any new pandemic strain, enabling it to be stockpiled and used as an immediate emergency response to any new influenza pandemic.

About The SOHO Group

The SOHO Group is the oldest and third largest pharmaceutical company in Indonesia. Over the past five years it has also been Indonesia's fastest growing pharma company, employing over 5,500 people with revenue growth of over 25% p.a. The SOHO Group manufactures and distributes medicines from global pharmaceutical companies as well as its own proprietary products.